Matches in Nanopublications for { ?s ?p "[Further, unlike the benefits observed with CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphomas (PTCL), other than ALK-positive ALCL, are relatively chemoresistant to this regimen.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 11 of
11
with 100 items per page.
- assertion description "[Further, unlike the benefits observed with CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphomas (PTCL), other than ALK-positive ALCL, are relatively chemoresistant to this regimen.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Further, unlike the benefits observed with CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphomas (PTCL), other than ALK-positive ALCL, are relatively chemoresistant to this regimen.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP336218.RAQFn62-evjsZPqFpJ_CAzNQwqHbe0hhRvn10c2soZmD4130_assertion description "[Further, unlike the benefits observed with CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphomas (PTCL), other than ALK-positive ALCL, are relatively chemoresistant to this regimen.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP336218.RAQFn62-evjsZPqFpJ_CAzNQwqHbe0hhRvn10c2soZmD4130_provenance.
- NP708392.RAoWlDF1ASCW1sGe2R8Yufdi4_xG6xtyfIDPXzHI5dWoU130_assertion description "[Further, unlike the benefits observed with CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphomas (PTCL), other than ALK-positive ALCL, are relatively chemoresistant to this regimen.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP708392.RAoWlDF1ASCW1sGe2R8Yufdi4_xG6xtyfIDPXzHI5dWoU130_provenance.
- assertion description "[Further, unlike the benefits observed with CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphomas (PTCL), other than ALK-positive ALCL, are relatively chemoresistant to this regimen.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Further, unlike the benefits observed with CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphomas (PTCL), other than ALK-positive ALCL, are relatively chemoresistant to this regimen.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP235533.RAdGaVBtRyMctYSWIouBlN3M31rzWW2a-QrYbOENWzSg4130_assertion description "[Further, unlike the benefits observed with CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphomas (PTCL), other than ALK-positive ALCL, are relatively chemoresistant to this regimen.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP235533.RAdGaVBtRyMctYSWIouBlN3M31rzWW2a-QrYbOENWzSg4130_provenance.
- NP351344.RABTf-8a1l48SqXC5-kndn_9KkZMHCaaC-KQl_BmO9BQM130_assertion description "[Further, unlike the benefits observed with CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphomas (PTCL), other than ALK-positive ALCL, are relatively chemoresistant to this regimen.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP351344.RABTf-8a1l48SqXC5-kndn_9KkZMHCaaC-KQl_BmO9BQM130_provenance.
- NP708508.RABno_RzgJ2KpnIn1soSM0g0QRrm_REvticTQr1aR_JsI130_assertion description "[Further, unlike the benefits observed with CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphomas (PTCL), other than ALK-positive ALCL, are relatively chemoresistant to this regimen.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP708508.RABno_RzgJ2KpnIn1soSM0g0QRrm_REvticTQr1aR_JsI130_provenance.
- NP708509.RAlclk_0czjGqo80fri28jc4sfuFErlFY_cupTBMcCvQM130_assertion description "[Further, unlike the benefits observed with CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphomas (PTCL), other than ALK-positive ALCL, are relatively chemoresistant to this regimen.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP708509.RAlclk_0czjGqo80fri28jc4sfuFErlFY_cupTBMcCvQM130_provenance.
- NP708506.RAwu9ReTaDIJg_QgtGcp0ftSU9IWW9MdJsj4U36MMwRHU130_assertion description "[Further, unlike the benefits observed with CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphomas (PTCL), other than ALK-positive ALCL, are relatively chemoresistant to this regimen.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP708506.RAwu9ReTaDIJg_QgtGcp0ftSU9IWW9MdJsj4U36MMwRHU130_provenance.